Trial Profile
To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor at Potentially Active Plasma Concentrations and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 27 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 28 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2017 New trial record